ALNYLAM PHARMACEUTICALS, INC. Gain (Loss) Related to Litigation Settlement
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Gain (Loss) Related to Litigation Settlement of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-13.
Discontinued › Income Statement › Other Income
us-gaap:GainLossRelatedToLitigationSettlement · last filed 2020-02-13
- ALNYLAM PHARMACEUTICALS, INC. gain (loss) related to litigation settlement for the quarter ending 2019-12-31 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. gain (loss) related to litigation settlement for the quarter ending 2019-09-30 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. gain (loss) related to litigation settlement for the quarter ending 2018-12-31 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. gain (loss) related to litigation settlement for the quarter ending 2018-09-30 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. gain (loss) related to litigation settlement for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- ALNYLAM PHARMACEUTICALS, INC. gain (loss) related to litigation settlement for fiscal 2018 was $20.56M.
- ALNYLAM PHARMACEUTICALS, INC. gain (loss) related to litigation settlement for fiscal 2017 was $0.00.
| Period end | Gain (Loss) Related to Litigation Settlement 3 month | Gain (Loss) Related to Litigation Settlement 6 month | Gain (Loss) Related to Litigation Settlement 9 month | Gain (Loss) Related to Litigation Settlement 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $0.00 derived: sum of 2 quarters · filed 2020-02-13 | $0.00 10-K · filed 2020-02-13 | |
| 2019-09-30 | $0.00 10-Q · filed 2019-10-31 | $0.00 10-Q · filed 2019-10-31 | ||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $0.00 derived: sum of 2 quarters · filed 2020-02-13 | $20.56M derived: sum of 3 quarters · filed 2020-02-13 | $20.56M 10-K · filed 2020-02-13 |
| 2018-09-30 | $0.00 10-Q · filed 2019-10-31 | $20.56M derived: sum of 2 quarters · filed 2019-10-31 | $20.56M 10-Q · filed 2019-10-31 | |
| 2018-06-30 | $20.56M 10-Q · filed 2019-08-06 | $20.56M 10-Q · filed 2019-08-06 | ||
| 2017-12-31 | $0.00 10-K · filed 2020-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |